[Supplementary Announcement to the Annual Report for the Year Ended December 31, 2022](index=1&type=section&id=Supplementary%20Announcement%20to%20the%20Annual%20Report%20for%20the%20Year%20Ended%20December%2031%2C%202022) [Risk Management Policy](index=1&type=section&id=Risk%20Management%20Policy) The Group implements a comprehensive risk management system, focusing on credit, liquidity, and operational risks through due diligence, multi-level approvals, and continuous monitoring - The Group has established a risk management system targeting credit, liquidity, interest rate, operational, and legal compliance risks, emphasizing comprehensive due diligence, independent data review, and a multi-layer approval process[10](index=10&type=chunk) - The credit risk management process includes several key measures: - **Due Diligence**: The Risk Management Department conducts thorough investigations into client background, financial status, and credit history through on-site visits and online verification[4](index=4&type=chunk) - **Approval Process**: A multi-level review system is in place, where the Risk Management Committee reviews credit assessment reports and grants final approval, with major decisions escalated to the Board of Directors[5](index=5&type=chunk) - **Post-drawdown Management**: This involves routine reviews, daily supervision of repayments, and prompt follow-up on overdue payments to identify potential defaults early[20](index=20&type=chunk) [Leasing Portfolio](index=3&type=section&id=Leasing%20Portfolio) As of December 31, 2022, the Group's net financing lease receivables decreased to RMB 201.2 million, primarily concentrated in medical equipment and largely secured by collateral and guarantees - The Group's total net receivables from financing lease services decreased from **RMB 288.6 million** as of December 31, 2021, to **RMB 201.2 million** as of December 31, 2022[6](index=6&type=chunk)[7](index=7&type=chunk)[14](index=14&type=chunk) Leasing Portfolio by Industry (Net Receivables) | Industry | 2022 (RMB '000) | 2022 (%) | 2021 (RMB '000) | 2021 (%) | | :--- | :--- | :--- | :--- | :--- | | Medical Equipment | 193,397 | 96.2 | 269,553 | 93.4 | | Printing | 4,303 | 2.1 | 15,189 | 5.3 | | Logistics | 3,469 | 1.7 | 3,854 | 1.3 | | **Total** | **201,169** | **100.0** | **288,596** | **100.0** | Leasing Portfolio by Risk Size (Net Receivables) | Risk Size (RMB) | 2022 (RMB '000) | 2022 (%) | 2021 (RMB '000) | 2021 (%) | | :--- | :--- | :--- | :--- | :--- | | Up to 1,000,000 | 173,162 | 86.1 | 260,053 | 90.1 | | 1,000,001 to 3,000,000 | 20,616 | 10.2 | 28,543 | 9.9 | | 3,000,001 to 5,000,000 | 7,391 | 3.7 | - | - | | **Total** | **201,169** | **100.0** | **288,596** | **100.0** | Leasing Portfolio by Guarantee (Net Receivables) | Guarantee Type | 2022 (RMB '000) | 2022 (%) | 2021 (RMB '000) | 2021 (%) | | :--- | :--- | :--- | :--- | :--- | | Collateralized and Guaranteed | 196,411 | 97.7 | 254,832 | 88.3 | | Guaranteed | 3,267 | 1.6 | 33,764 | 11.7 | | Collateralized | 1,491 | 0.7 | - | - | | **Total** | **201,169** | **100.0** | **288,596** | **100.0** |

Revenue and Profitability - The Group recorded a revenue of RMB 15.6 million from maternal and child postpartum care industry services during the Period, reflecting a decline due to epidemic control measures[4]. - Revenue from the medical equipment and consumables trading business reached RMB 147.2 million, marking a significant growth in the Group's revenue structure[5]. - Total revenue for the six months ended June 30, 2023, was RMB 175,623,000, an increase from RMB 142,466,000 in the same period of 2022, representing a growth of approximately 23.2%[103]. - Income from postpartum care services was RMB 15,571,000 for the six months ended June 30, 2023, compared to RMB 24,712,000 in the same period of 2022, indicating a decline of about 37.1%[103]. - Profit attributable to owners of the Company decreased to approximately RMB 6.1 million for the six months ended June 30, 2023, down from RMB 8.1 million in the prior period[13]. - Profit before income tax for the six months ended June 30, 2023, was RMB 7,336,000, down from RMB 9,698,000 in the same period of 2022, reflecting a decrease of approximately 24.4%[103]. - Total comprehensive income for the period attributable to owners of the Company was RMB 6,115,000, compared to RMB 8,103,000 in the same period of 2022, indicating a decline of about 24.5%[103]. Expenses and Costs - Other operating expenses decreased from approximately RMB 24.4 million in the prior period to about RMB 21.0 million in the current period, primarily due to reduced miscellaneous expenses in the maternal and child postpartum care business[11]. - The Group's total employee costs for the period were approximately RMB 20.7 million, slightly up from RMB 20.6 million in the prior period[19]. - Staff costs for the six months ended June 30, 2023, were RMB 20,712,000, slightly increasing from RMB 20,639,000 in the same period of 2022, showing a marginal increase of about 0.4%[103]. Dividends and Shareholder Information - The Group does not recommend the payment of an interim dividend for the Period, consistent with the prior period[12]. - The final dividend declared for the period is HKD 0.025 per share, totaling HKD 10,000,000 (approximately RMB 9,140,000)[58]. - The ultimate controlling shareholders, Mr. Zhang Junshen and Mr. Zhang Junwei, are deemed to be interested in 75.0% of the issued share capital of the Company[1]. - Mr. Zhang Junshen holds 300,000,000 Shares, which includes 219,801,980 Shares held by Hero Global and 80,198,020 Shares as a party acting-in-concert with Mr. Zhang Junwei[2]. - Mr. Zhang Junwei also holds 300,000,000 Shares, consisting of 80,198,020 Shares held by Icon Global and 219,801,980 Shares as a party acting-in-concert with Mr. Zhang Junshen[3]. Financial Position and Assets - As of June 30, 2023, trade receivables amounted to RMB 100,091,000, down from RMB 132,435,000 as of December 31, 2022, indicating a reduction of approximately 24.3%[83]. - The company maintained a strong cash position with bank balances and cash totaling RMB 18,533,000 as of June 30, 2023, compared to RMB 13,707,000 at the end of 2022[128]. - The company’s total liabilities decreased from RMB 33,348,000 to RMB 28,500,000, a decline of approximately 14.5%[65]. - The net current assets as of June 30, 2023, were RMB 209,775,000, down from RMB 233,689,000 at the end of 2022[128]. - The total reportable segment assets as of June 30, 2023, amounted to RMB 532,483,000, with finance leasing assets at RMB 241,750,000, trading business assets at RMB 205,670,000, and postpartum care service assets at RMB 85,063,000[160]. Compliance and Governance - The Company has confirmed compliance with the Code of Conduct regarding securities transactions by the Directors for the reporting period[33]. - The Audit Committee has reviewed the unaudited condensed consolidated financial statements for the six months ended 30 June 2023, ensuring compliance with applicable accounting standards and GEM Listing Rules[54]. - The Company has adopted the corporate governance practices as per the GEM Listing Rules, ensuring proper regulation of business activities and decision-making processes[31]. - The independent non-executive Directors confirmed compliance with the Deed of Non-competition by all controlling shareholders during the period[44]. Market Outlook and Strategy - The Group anticipates that the health industry will become a new economic breakthrough point with significant value-added potential post-epidemic[5]. - The Group plans to continue increasing investment in various businesses despite the grim global economic situation[6]. - The management discussed strategies for market expansion and new product development, although specific figures were not disclosed in the provided content[89]. Cash Flow and Investments - Net cash generated from operating activities for the six months ended June 30, 2023, was RMB 21,481,000, compared to a net cash used of RMB 32,253,000 in the same period of 2022[136]. - Net cash used in investing activities was RMB 6,214,000 for the six months ended June 30, 2023, compared to a net cash generated of RMB 3,810,000 in the same period of 2022[136]. - The net decrease in cash and cash equivalents for the six months ended June 30, 2023, was RMB 41,810,000, an improvement from a decrease of RMB 68,487,000 in the same period of 2022[136]. Segment Performance - Reportable segment revenue for finance leasing service was RMB 4,975,000, while postpartum care service generated RMB 11,165,000, and trading of medical equipment and consumables reported a loss of RMB 832,000[143]. - Reportable segment profit before income tax for the same period was RMB 7,336,000, with a profit of RMB 2,749,000 from finance leasing, RMB 16,999,000 from trading, and a loss of RMB 2,208,000 from postpartum care services[160].

Ziyuanyuan Holdings Group Limited 紫元元控股集團有限公司 （於開曼群島註冊成立的有限公司） 8223 （股份代號： ） 截至二零二三年六月三十日止六個月 中期業績公告 GEM 香港聯合交易所有限公司（「聯交所」） 的特色 GEM 乃為較於聯交所上市的其他公司可能帶有更高投資風險的中小型公司而設的市場。有意 投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，於 買賣的證券可能會較於聯交所主板買賣的證 GEM 券承受較大的市場波動風險，同時無法保證於 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不就因本報告全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 GEM GEM 本公告乃遵照聯交所 證券上市規則（「 上市規則」）的規定而提供有關紫元元控股集 團有限公司（「本公司」）的資料，本公司之董事（「董事」）願就本報告共同及個別地承擔全部責 任。董事在作出一切合理查詢後，確認就彼等所知及所信 ...

Revenue and Profit Performance - Total revenue for Q1 2023 was RMB 61.61 million, a significant increase from RMB 31.75 million in Q1 2022[11] - Revenue from medical equipment and consumables trading surged to RMB 45.01 million in Q1 2023, up from RMB 8.11 million in Q1 2022[11] - Postpartum care services revenue decreased to RMB 7.67 million in Q1 2023 from RMB 11.87 million in Q1 2022[11] - Finance leasing income dropped to RMB 8.67 million in Q1 2023 compared to RMB 11.27 million in Q1 2022[11] - Profit before income tax increased to RMB 2.44 million in Q1 2023 from RMB 2.13 million in Q1 2022[11] - Net profit attributable to owners of the company was RMB 2.08 million in Q1 2023, slightly down from RMB 2.16 million in Q1 2022[11] - Earnings per share (basic and diluted) were RMB 0.52 cents in Q1 2023, compared to RMB 0.54 cents in Q1 2022[11] - Revenue for the period includes finance leasing income, interest income on loan receivables, income from postpartum care services, and income from trading of medical equipment and consumables in the PRC[35] - Revenue from finance leasing services decreased to RMB8.67 million in Q1 2023 from RMB11.27 million in Q1 2022[50] - Revenue from maternal and child postpartum care services decreased to RMB7.67 million in Q1 2023 from RMB11.87 million in Q1 2022[50] - Revenue from trading of medical equipment and consumables increased significantly to RMB45.01 million in Q1 2023 from RMB8.11 million in Q1 2022[50] - The Group's medical equipment and consumables trading business achieved revenue of RMB45.0 million in Q1 2023[67] - Profit attributable to owners of the Company was approximately RMB2.08 million in Q1 2023, compared to RMB2.16 million in Q1 2022[69] - Revenue increased by approximately RMB 29.9 million or 94.0%, from RMB 31.8 million in the prior period to RMB 61.6 million in the current period, primarily driven by a significant increase in medical equipment and consumables trade revenue from RMB 8.1 million to RMB 45.0 million[83] - Revenue increased by approximately RMB29.9 million (94.0%) from RMB31.8 million to RMB61.6 million, driven by a significant rise in income from trading medical equipment and consumables from RMB8.1 million to RMB45.0 million[103] - Medical equipment and consumables trading business achieved revenue of RMB45.0 million, marking a breakthrough growth in the company's revenue structure[100] - Finance leasing income decreased from RMB11.8 million to RMB8.9 million, while postpartum care services income decreased from RMB11.9 million to RMB7.7 million[103] - Profit and total comprehensive income attributable to owners of the company decreased from RMB 2.2 million to RMB 2.1 million, primarily due to a decrease in revenue from finance leasing services and maternal and child postpartum care industry services, as well as an increase in finance costs[114] Costs and Expenses - Total interest expense on financial liabilities not measured at fair value through profit or loss was RMB 3,990 thousand in 2023, compared to RMB 3,186 thousand in 2022[37] - Current tax for PRC Enterprise Income Tax was RMB 234 thousand in 2023, up from RMB 213 thousand in 2022[39] - Deferred tax increased significantly to RMB 413 thousand in 2023 from RMB 24 thousand in 2022[39] - Total staff costs decreased to RMB 10,196 thousand in 2023 from RMB 11,259 thousand in 2022[44] - Cost of inventories sold surged to RMB 36,532 thousand in 2023 from RMB 6,611 thousand in 2022[44] - Research and development costs recognized as an expense increased to RMB 848 thousand in 2023 from RMB 123 thousand in 2022[44] - Short-term lease payments decreased to RMB 356 thousand in 2023 from RMB 1,411 thousand in 2022[44] - Medical equipment and consumables sold cost increased to approximately RMB 36.5 million from RMB 6.6 million in the prior period[84] - Finance costs increased from approximately RMB 3.2 million to RMB 4.0 million, primarily due to an increase in interest on bank and other borrowings from RMB 3.0 million to RMB 3.7 million[90] - Cost of sales for medical equipment and consumables business increased to approximately RMB36.5 million from RMB6.6 million in the prior period[107] - Staff costs decreased from RMB10.1 million to approximately RMB9.5 million, primarily due to a reduction in headcount[108] - Other operating expenses decreased from approximately RMB12.0 million to RMB10.4 million, mainly due to reductions in postpartum care business expenses, short-term lease payments, and depreciation of property, plant, and equipment[111] - Other operating expenses decreased from approximately RMB 12.0 million to RMB 10.4 million, mainly due to reductions in miscellaneous expenses for maternal and child postpartum care business (from RMB 3.2 million to RMB 2.1 million), short-term lease payments (from RMB 1.4 million to RMB 0.4 million), and depreciation of property, plant, and equipment (from RMB 1.9 million to RMB 1.1 million)[112] Taxation - The tax rate for most PRC subsidiaries is 25%, except for one subsidiary recognized as a high technology enterprise, which enjoys a preferential tax rate of 15%[39] - Certain PRC subsidiaries qualified as small low-profit enterprises, with taxable income not exceeding RMB 1.0 million taxed at 12.5%, and income exceeding RMB 1.0 million but not exceeding RMB 3.0 million taxed at 50% of the taxable income[90] - The Group's subsidiaries in China are subject to an enterprise income tax rate of 25%, except for one subsidiary which qualifies for a preferential rate of 15%[59] Corporate Governance and Shareholding - The company's controlling shareholders, Mr. Zhang Junshen and Mr. Zhang Junwei, are deemed to be interested in 75.0% of the issued share capital of the company[1] - The company's issued share capital as of 31 March 2023 was HK$40,000,000, with 400,000,000 ordinary shares issued at HK$0.1 per share[114] - Mr. Zhang Junshen and Mr. Zhang Junwei each hold 300,000,000 shares, representing a 75% stake in the company[116] - The company did not recommend the payment of an interim dividend for the period[114] - The company's capital structure has remained unchanged since its listing on the GEM of the Stock Exchange on 9 July 2018[114] - The company confirmed that all directors complied with the Code of Conduct regarding securities transactions for the three months ended 31 March 2023[135] - The Audit Committee reviewed the unaudited condensed consolidated financial statements and confirmed compliance with applicable accounting standards and GEM Listing Rules[139] - The company has not purchased, sold, or redeemed any of its listed securities during the period[131] - The company maintains high corporate governance standards, with compliance to the CG Code except for a deviation from code provision C.2.1[129] - The controlling shareholders, Mr. Zhang Junshen and Mr. Zhang Junwei, are deemed to be interested in 75.0% of the issued share capital of the company through Hero Global and Icon Global respectively[150] - Ms. Tang Yiping, the spouse of Mr. Zhang Junshen, is deemed to be interested in all shares in which Mr. Zhang Junshen is interested[150] - As of 31 March 2023, the directors were not aware of any other person (other than the disclosed directors or chief executive) who had or was deemed to have interests or short positions in the company's shares, underlying shares, or debentures[150] - The company and its subsidiaries did not purchase, sell, or redeem any of the company's listed securities during the period and up to the date of the report[152] - The company has adopted and complied with the Corporate Governance Code (CG Code) except for a deviation from code provision C.2.1[153] - The Audit Committee consists of non-executive director Mr. Lyu Di and independent non-executive directors Mr. Chan Chi Fung Leo and Dr. Deng Bin, with Mr. Chan Chi Fung Leo serving as the chairman[162] - The Audit Committee has reviewed the unaudited condensed consolidated financial statements for the three months ended 31 March 2023 and considers them to be in compliance with applicable accounting standards, GEM Listing Rules, and other legal requirements[168] - The roles of chairman and chief executive officer are both held by Mr. Zhang Junshen, which the Board believes ensures strong and consistent leadership without impairing the balance of power and authority[171] - The Group has established an Audit Committee in compliance with the GEM Listing Rules and the CG Code, with written terms of reference[172] - The Board comprises experienced and high-caliber individuals who meet regularly to discuss operational issues[171] - The Board has full confidence in Mr. Zhang Junshen's dual role, believing it benefits the Company's business prospects[171] - The Audit Committee was established pursuant to a resolution passed by the Directors on 12 June 2018[172] Business Strategy and Outlook - The Group recorded a segmental loss in maternal and child postpartum care services due to pandemic-related restrictions[75] - The company remains optimistic about sustaining its core business despite economic uncertainties caused by Covid-19, focusing on leveraging its existing client base and exploring opportunities in the healthcare industry[102] - The healthcare industry is expected to be a new economic breakthrough with significant value-added potential post-pandemic, prompting the company to focus on medical equipment finance leasing and trading[102] - The company has strategically entered the medical equipment and consumables trading business, targeting sectors such as medical aesthetics, dental, maternal and child care, and large hospital equipment[100] Financial Position and Equity - Total equity attributable to owners of the company increased to RMB 308.94 million as of March 31, 2023, from RMB 306.86 million at the start of the year[13] - Reversal of impairment loss of approximately RMB 0.9 million was recognized, mainly due to a decrease in total trade receivables[87]

Ziyuanyuan Holdings Group Limited 紫元元控股集團有限公司 （於開曼群島註冊成立的有限公司） 8223 （股份代號： ） 截至二零二三年三月三十一日止三個月 第一季度業績公告 GEM 香港聯合交易所有限公司（「聯交所」） 的特色 GEM 乃為較於聯交所上市的其他公司可能帶有更高投資風險的中小型公司而設的市場。有意 投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，於 買賣的證券可能會較於聯交所主板買賣的證 GEM 券承受較大的市場波動風險，同時無法保證於 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 GEM 本公告乃遵照 證券上市規則的規定而提供有關紫元元控股集團有限公司（「本公司」）的資 料，本公司之董事（「董事」）願就本公告共同及個別地承擔全部責任。董事在作出一切合理查 詢後，確認就彼等所知及所信，本公告所載資料在各重要方 ...

Business Operations - The Group is primarily engaged in providing medical equipment finance leasing services, maternal and child postpartum care industry services, and trading of medical equipment and consumables in the PRC[26] - The Group's operations are focused on the PRC market, indicating a strategic emphasis on this region for growth and service delivery[27] - The Group's revenue doubled from 2021 to over RMB 300 million, indicating significant growth in its financial leasing services focused on medical equipment[29] - The Group provided finance leasing services to approximately 4,300 SMEs customers across 30 provinces in China, generating revenue of RMB 37.3 million during the year[48] - The maternal and child postpartum care industry services recorded revenue of RMB 50.8 million, but faced a segmental loss of RMB 1.7 million due to operational restrictions from epidemic control measures[55] Financial Performance - The financial year ended on December 31, 2022, marking the end of the reporting period for the Group[26] - The Group is optimistic about sustaining its core business despite economic uncertainties due to Covid-19, actively seeking opportunities to leverage its existing client base[29] - The Group's profit attributable to owners increased to approximately RMB 15.8 million for the Year, up from RMB 5.5 million in the Prior Year, primarily due to increased income from trading medical equipment and consumables[73] - Finance costs rose from approximately RMB 8.0 million in the Prior Year to approximately RMB 13.1 million for the Year, mainly due to increased interest on bank and other borrowings[72] - As of December 31, 2022, the Group's bank balances and cash were approximately RMB 13.7 million, down from RMB 33.5 million in 2021[76] - The Group's total equity as of December 31, 2022, was approximately RMB 310.8 million, compared to RMB 304.3 million in 2021[76] - The gearing ratio increased to approximately 42.4% as of December 31, 2022, from 38.6% in 2021, attributed to increased borrowings for business expansion[76] Risk Management - The Group's financial leasing services are focusing on risk management to improve asset quality and reduce risks, protecting shareholders' interests[34] - The Group has established a risk management system to address various risks including credit, liquidity, and operational risks associated with finance leasing services[49] - The Group continues to monitor and improve its risk management system to adapt to changes in market conditions and regulatory environments[49] Strategic Growth - The healthcare industry is expected to become a new economic breakthrough post-pandemic, with the Group positioning itself in the medical equipment leasing and trading sectors[29] - By 2025, China aims to establish a comprehensive medical equipment standard system, which is expected to drive growth in the high-end medical equipment market[34] - The full liberalization of the "three-child policy" is anticipated to increase demand for maternal and child postpartum care services, providing growth opportunities for the Group[37] - The Group plans to build a comprehensive mother and baby ecosystem with full industry chain coverage in the maternal and child postpartum care industry[37] - The Group will continue to increase investment across various businesses to find opportunities amid global economic challenges[38] Corporate Governance - The company emphasizes the importance of its Board in providing effective leadership and ensuring transparency and accountability in operations[100] - The Board has delegated various responsibilities to its committees to enhance corporate governance practices[105] - The company has been compliant with the GEM listing rules and corporate governance code, except for a specific deviation noted[103] - The Company has established a code of conduct and compliance manual applicable to Directors and employees[129] - The Board meets the requirements of the GEM Listing Rules, ensuring effective governance and oversight[129] - The Company has arranged appropriate liability insurance coverage for all Directors, which will be reviewed by the Board regularly[135] - The Company has implemented corporate governance practices in line with the GEM Listing Rules, ensuring transparency and accountability in operations[131] Board Composition and Responsibilities - The current Board composition includes two executive Directors, one non-executive Director, and three INEDs, ensuring a balance of skills and experiences[136] - The Board believes that the current structure does not impair the balance of power and authority between the Board and management[143] - The Company has established a Nomination and Corporate Governance Committee to oversee board appointments and governance practices[146] - The Board retains decision-making authority over significant transactions, requiring prior approval for any major dealings[133] - The independent directors provide critical insights and advice to the Board, enhancing decision-making processes[92] Employee and Supplier Relations - The Group employs a total of 281 employees, with 62 male and 219 female employees, indicating a diverse workforce[185] - During the Reporting Period, the Group had approximately 219 suppliers, all of which are from the PRC, and none failed to meet the Group's requirements[157] - The Group focuses on maintaining long-term relationships with suppliers that have good creditworthiness and quality products[157] - The Group is committed to providing a safe and equitable work environment for employees, adhering to labor laws in China and Hong Kong[153] Environmental Responsibility - The Group has implemented measures to reduce water consumption, although specific wastewater data could not be provided due to lack of sub-metering[181] - The Company has implemented measures for the disposal and recycling of computer-related products[149] Dividend and Shareholder Returns - A final dividend of HK 2.5 cents per share is recommended for the financial year 2022, reflecting the Group's commitment to returning value to shareholders[42] Acquisition and Profit Guarantees - The profit guarantee for the acquisition of Desheng Meimei requires a net profit after tax of no less than RMB 1.8 million for the period ending December 31, 2022, and RMB 2.2 million for the year ending December 31, 2023[60] - The actual profit after tax for Desheng Meimei from the completion date to December 31, 2022, was approximately RMB 0.9 million, resulting in the profit guarantee not being met[61] - The Group plans to exercise the option to request the vendor to repurchase the 51% equity interest in Desheng Meimei due to unmet profit guarantees, with the repurchase anticipated in the second half of 2023[61] - The Group acquired a 54% equity interest in Wuhan Jiaenbei Health Management Co., Ltd. for a consideration of RMB 3.24 million[64] - Jiaenbei is guaranteed to achieve a net profit after tax of no less than RMB 1.0 million for the periods ending December 31, 2021, 2022, and 2023[67]

Ziyuanyuan Holdings Group Limited 紫元元控股集團有限公司 （於開曼群島註冊成立的有限公司） 8223 （股份代號： ） 截至二零二二年十二月三十一日止年度 全年業績公告 GEM 香港聯合交易所有限公司（「聯交所」） 的特色 GEM 乃為較於聯交所上市的其他公司可能帶有更高投資風險的中小型公司而設的市場。有意 投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳考慮後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，於 買賣的證券可能會較於聯交所主板買賣的證 GEM 券承受較大的市場波動風險，同時無法保證於 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 GEM GEM 本公告乃遵照聯交所 證券上市規則（「 上市規則」）的規定而提供有關紫元元控股集 團有限公司（「本公司」）的資料，本公司之董事（「董事」）願就本公告共同及個別地承擔全部責 任。董事在作出一切合理查詢後，確認就彼等所知及所 ...

Financial Performance - Total revenue for the three months ended September 30, 2022, was RMB 93,214,000, an increase from RMB 26,872,000 in the same period of 2021[15]. - Profit before income tax for the three months ended September 30, 2022, was RMB 1,310,000, up from RMB 397,000 in the prior year[15]. - The profit and total comprehensive income for the period attributable to owners of the Company was RMB 930,000 for the three months ended September 30, 2022, compared to RMB 12,000 in the same period of 2021[15]. - Total revenue for the nine months ended September 30, 2022, was RMB 235,680,000, an increase from RMB 79,315,000 in the same period of 2021[15]. - The Group's total comprehensive income for the nine months ended September 30, 2022, was RMB 9,015,000, compared to RMB 4,424,000 in the prior year[15]. - Profit for the period after tax for the three months ended September 30, 2022, was RMB 230,000, compared to RMB 19,000 in the same period of 2021, reflecting a substantial increase[39]. - Profit attributable to owners of the Company for the Period was approximately RMB 9.0 million, up from RMB 3.9 million in the Prior Period, mainly due to increased income from trading of medical equipments[90]. Revenue Sources - Finance leasing income for the three months ended September 30, 2022, was RMB 11,295,000, slightly up from RMB 11,210,000 in the prior year[15]. - Income from postpartum care services and medical equipment trading reached RMB 16,204,000 for the three months ended September 30, 2022, compared to RMB 13,478,000 in the same period of 2021[15]. - The Group reported a significant increase in income from trading of medical equipment and consumables, reaching RMB 65,711,000 for the three months ended September 30, 2022[15]. - Revenue from finance leasing services during the nine months ended September 30, 2022, was RMB 31.1 million, serving approximately 4,000 SMEs across 30 provinces in China[61]. - Maternal and child postpartum care services generated revenue of RMB 40.9 million during the same period[63]. - The trading of medical equipment and consumables business achieved revenue of RMB 163.6 million during the nine months ended September 30, 2022[68]. Costs and Expenses - Interest on bank borrowing increased significantly to RMB 3,210,000 for the three months ended September 30, 2022, compared to RMB 1,949,000 in the same period of 2021, representing a 64.5% increase[36]. - Total staff costs for the three months ended September 30, 2022, were RMB 11,568,000, up 21.2% from RMB 9,545,000 in the same period of 2021[44]. - Cost of inventories sold surged to RMB 60,264,000 for the three months ended September 30, 2022, compared to RMB 1,909,000 in the same period of 2021, indicating a significant increase[44]. - Staff costs increased from RMB 25.3 million in the Prior Period to approximately RMB 31.2 million for the Period, primarily due to an increase in headcount and salaries[78]. - Other operating expenses rose from approximately RMB 38.2 million for the Prior Period to approximately RMB 41.9 million for the Period, mainly due to increased expenses in the postpartum care business[81]. - Finance costs increased from approximately RMB 6.0 million in the Prior Period to approximately RMB 9.7 million for the Period, driven by higher interest on bank and other borrowings[84]. Shareholder Information - As of September 30, 2022, Mr. Zhang Junshen and Mr. Zhang Junwei each hold 300,000,000 shares, representing a 75% interest in the Company[98][100]. - The ultimate controlling shareholders, Mr. Zhang Junshen and Mr. Zhang Junwei, confirmed their concert party arrangement on February 24, 2017, acknowledging their joint interests[100]. - The Company has a total of 75% of its issued share capital deemed to be held by the controlling shareholders[100]. - Ms. Tang Yiping holds a spouse interest in 300,000,000 shares, also representing a 75% interest in the Company[120]. Corporate Governance - The Company has complied with the GEM Listing Rules regarding the disclosure of interests and short positions[110]. - The Company has complied with the provisions of the Corporate Governance Code, except for a deviation from code provision A.2.1 regarding the separation of roles of chairman and CEO[135][140]. - The Audit Committee reviewed the unaudited condensed consolidated financial statements for the nine months ended September 30, 2022, confirming compliance with applicable accounting standards and GEM Listing Rules[147]. - The Company considers high standards of corporate governance essential for its continuous growth[135]. Future Outlook - The Group remains optimistic about sustaining core business despite economic uncertainties due to Covid-19, focusing on leveraging the current client base for growth[69]. - The Group plans to continue investing in various businesses to find opportunities amidst challenges, aiming to enhance corporate and social value[70]. - The healthcare industry is expected to become a new economic breakthrough post-pandemic, with significant value-added potential[69]. - The Group is strategically focusing on finance leasing services and medical equipment related to the oral cavity and maternity and child industry[69].

Financial Performance - For the six months ended 30 June 2022, the company reported a revenue of HKD 50 million, representing a 20% increase compared to the same period last year[28]. - The net profit for the same period was HKD 10 million, which is a 15% increase year-on-year[28]. - Total revenue for the six months ended June 30, 2022, was RMB 142,466,000, an increase of 171.5% compared to RMB 52,443,000 for the same period in 2021[29]. - Profit and total comprehensive income for the period attributable to owners of the Company was RMB 8,103,000, compared to RMB 3,865,000 in the same period of 2021, representing a growth of 109.5%[29]. - Basic earnings per share for the six months ended June 30, 2022, was RMB 5,948, compared to RMB 854 for the same period in 2021, reflecting a significant increase[86]. - The Company reported a total comprehensive income of RMB 8,103,000 for the six months ended June 30, 2022, compared to RMB 3,865,000 for the same period in 2021, representing a growth of approximately 109.5%[36]. - Profit before income tax for the six months ended June 30, 2022, was RMB 9,698,000[57]. - The Company’s retained profits increased to RMB 66,135,000 as of June 30, 2022, from RMB 58,032,000 at the beginning of the year, marking an increase of about 13.9%[36]. Revenue Breakdown - Revenue for the six months ended June 30, 2022, was RMB 142,466,000, a significant increase from RMB 52,443,000 in the same period of 2021, representing a growth of 171.5%[52]. - Trading of medical equipment and consumables generated revenue of RMB 97,916,000 for the six months ended June 30, 2022, a substantial increase from RMB 2,780,000 in the same period of 2021, indicating a growth of 3515.4%[52]. - Income from postpartum care services increased to RMB 24,712,000, compared to RMB 23,459,000 in the same period of 2021, showing a growth of 5.3%[52]. - Finance leasing income decreased to RMB 19,317,000 for the six months ended June 30, 2022, down from RMB 25,678,000 in the prior year, reflecting a decline of 24.5%[52]. User Engagement and Market Expansion - User data showed a growth in active users by 25%, reaching a total of 200,000 users[28]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2023[28]. - New product development includes the launch of a mobile application, expected to increase user engagement by 40%[28]. - The Company plans to continue its market expansion and product development strategies to enhance its competitive position in the industry[41]. Research and Development - The company has allocated HKD 5 million for research and development in new technologies for the upcoming fiscal year[28]. - Research and development costs recognized as an expense for the six months ended June 30, 2022, were RMB 436,000, compared to RMB 1,043,000 for the same period in 2021, showing a decrease in R&D expenditure[80]. Financial Position and Assets - Current assets totaled RMB 389,074,000 as of June 30, 2022, down from RMB 407,070,000 at the end of 2021, reflecting a decrease of 4.4%[31]. - Total assets less current liabilities were RMB 376,089,000 as of June 30, 2022, down from RMB 388,009,000 at the end of 2021, indicating a decrease of 3.1%[33]. - The Company’s total assets as of June 30, 2022, were RMB 311,801,000, reflecting a slight increase from RMB 304,322,000 at the beginning of the year[36]. Liabilities and Borrowings - The Company’s bank and other borrowings decreased to RMB 103,490,000 as of June 30, 2022, from RMB 117,496,000 at the end of 2021, a reduction of 11.9%[33]. - Total bank and other borrowings reached RMB 158,535,000, down 17% from RMB 191,205,000 as of December 31, 2021[147]. - Non-current liabilities decreased to RMB 55,045,000 from RMB 73,709,000, reflecting a reduction of 25%[147]. Impairment and Credit Risk - The total impairment losses recognized for the six months ended June 30, 2022, were RMB 4,736, compared to RMB 3,285 for the same period in 2021, indicating an increase in impairment[113]. - The impairment losses recognized on trade receivables amounted to RMB 736 for the six months ended June 30, 2022, with a 12-month expected credit loss allowance of RMB 736[113]. - The ageing analysis of finance lease receivables showed that past due amounts were RMB 10,852,000 as of June 30, 2022, compared to RMB 11,828,000 as of December 31, 2021[99]. Taxation - The total tax charge for the six months ended June 30, 2022, was RMB 1,763,000, compared to RMB 218,000 for the same period in 2021, indicating a rise in tax obligations due to increased profitability[78]. - The Company’s PRC subsidiaries are subject to a standard enterprise income tax rate of 25%, with one subsidiary benefiting from a reduced rate of 15% as a high technology enterprise[76]. Staff Costs - Total staff costs for the six months ended June 30, 2022, amounted to RMB 22,602,000, an increase of 30.7% from RMB 17,317,000 in the same period of 2021[80]. - Staff costs recognized in profit or loss for the six months ended June 30, 2022, were RMB 20,639,000, up from RMB 16,296,000 in the same period of 2021, marking a 26.5% increase[80].

Financial Performance - Total revenue for the three months ended March 31, 2022, was RMB 31,753,000, representing a 40.6% increase from RMB 22,553,000 in the same period of 2021[15] - Profit and total comprehensive income for the period was RMB 1,895,000, a decline of 38.3% compared to RMB 3,071,000 in the first quarter of 2021[15] - Earnings per share attributable to owners of the Company for the period was RMB 0.54, down from RMB 0.75 in the same period last year[13] - The profit attributable to owners of the Company for the three months ended 31 March 2022 was approximately RMB 2,155,000, compared to RMB 3,011,000 for the same period in 2021, indicating a decrease of about 28.4%[67] - The total profit and comprehensive income attributable to the owners of the company for the three months ended March 31, 2022, was approximately RMB 2.2 million, a decrease from RMB 3.0 million in the same period of 2021, primarily due to increased employee costs, operating expenses, and financing costs[104] Revenue Breakdown - Income from postpartum care services increased to RMB 11,869,000, up 26.1% from RMB 9,400,000 in the previous year[15] - Revenue from trading of medical equipment and consumables reached RMB 8,111,000 in Q1 2022, with no prior year comparison available[44] - Income from postpartum care services was RMB 11,869,000, an increase of 26.3% compared to RMB 9,400,000 in Q1 2021[44] - For the three months ended 31 March 2022, the Group's revenue increased by approximately RMB9.2 million or approximately 40.8% to approximately RMB31.8 million compared to RMB22.6 million for the same period in 2021[88] - Revenue from postpartum care services increased from approximately RMB9.4 million for the three months ended 31 March 2021 to approximately RMB11.9 million for the same period in 2022[88] - The income from trading of medical equipments and consumables was approximately RMB8.1 million for the three months ended 31 March 2022, compared to nil for the same period in 2021[88] Cost and Expenses - The Group's cost of sales was RMB 6,611,000, with no corresponding figure reported for the previous year[15] - Staff costs increased to RMB 10,136,000, up from RMB 7,597,000 in the same period of 2021[15] - The total staff costs for the three months ended 31 March 2022 amounted to RMB 11,259,000, an increase from RMB 8,054,000 in the same period of 2021, representing a growth of approximately 39.4%[65] - Other operating expenses increased from approximately RMB10.5 million for the three months ended 31 March 2021 to approximately RMB12.0 million for the three months ended 31 March 2022[95] - The other operating expenses for the postpartum care business rose from approximately RMB5.8 million for the three months ended 31 March 2021 to approximately RMB8.5 million for the three months ended 31 March 2022[95] - Finance costs increased from approximately RMB2.0 million for the three months ended 31 March 2021 to approximately RMB3.2 million for the three months ended 31 March 2022, primarily due to an increase in bank borrowing interest[99] Assets and Liabilities - The Group's total assets as of March 31, 2022, were RMB 306,217,000, compared to RMB 309,637,000 as of March 31, 2021[28] - Non-controlling interests at the end of the period were RMB 4,539,000, down from RMB 4,258,000 in the previous year[28] Shareholding and Governance - The number of issued ordinary shares as of 31 March 2022 was 400,000,000, with an issued share capital of HK$40,000,000[103] - The Company has confirmed that all Directors have complied with the Code of Conduct regarding securities transactions for the three months ended March 31, 2022[151] - The Company has adopted and complied with the Corporate Governance Code, except for a deviation from code provision A.2.1[141] - The roles of chairman and chief executive officer are held by Mr. Zhang Junshen, which the Board believes does not impair the balance of power and authority[149] - The Company maintains a high standard of corporate governance as essential for its continuous growth[141] Future Outlook and Strategy - The Group is optimistic about sustaining core business despite economic uncertainties due to the Covid-19 outbreak[83] - The Group plans to leverage its current client base to seek growth opportunities in the healthcare industry post-pandemic[83] - The Group aims to diversify its income streams through the development of trading medical equipments and consumables business[83] - Future outlook includes potential strategies for market expansion and product development to enhance revenue streams[104] Compliance and Audit - The Audit Committee reviewed the unaudited condensed consolidated financial statements for the three months ended March 31, 2022, and confirmed compliance with applicable accounting standards and GEM Listing Rules[159] - The financial information in the report has not been audited, but adequate disclosures have been made according to legal requirements[159] - The Audit Committee is chaired by Mr. Chan Chi Fung Leo, who holds the necessary professional qualifications[158]